{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T17:15:44Z","timestamp":1783098944189,"version":"3.54.6"},"reference-count":11,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2018,1,25]],"date-time":"2018-01-25T00:00:00Z","timestamp":1516838400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2018,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>A recent regulatory warning and case reports have described the development of muscle complications with the use of 5\u2010\u03b1 reductase inhibitors (5ARIs). We wished to determine if there was a link between rhabdomyolysis and 5ARI usage.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We used a matched cohort design and linked administrative data from the province of Ontario, Canada, to investigate the risk of rhabdomyolysis in men using either finasteride or dutasteride. A total of 99 covariates were measured. We identified 93\u00a0197 men \u226566\u00a0years of age who initiated a new prescription for a 5ARI, and they were matched using a propensity score to an equal number of men not prescribed a 5ARI.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>New initiation of 5ARIs was not associated with a significantly increased risk of rhabdomyolysis (hazard ratio [HR] 1.21, 95% confidence interval [CI], 1.00\u20101.48, <jats:italic>P<\/jats:italic>\u00a0=\u00a0.06). When we examined the risk of rhabdomyolysis in the year prior to the initiation of a 5ARI, we found that men who would go on to use a 5ARI in the future had an elevated risk of rhabdomyolysis even prior to starting the medication (HR 1.31, 95% CI, 1.05\u20101.64, <jats:italic>P<\/jats:italic>\u00a0=\u00a0.01). Our secondary outcome of myositis and myopathy was significantly higher among 5ARI users (HR 1.63, 95% CI, 1.48\u20101.80, <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a0.01), and this risk was not present prior to 5ARI usage.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>5\u2010\u03b1 reductase inhibitors do not appear to be associated with the development of rhabdomyolysis; however, they may be associated with an increased risk of myopathy and myositis.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.4383","type":"journal-article","created":{"date-parts":[[2018,1,25]],"date-time":"2018-01-25T05:32:40Z","timestamp":1516858360000},"page":"351-355","source":"Crossref","is-referenced-by-count":7,"title":["Risk of rhabdomyolysis from 5\u2010\u03b1 reductase inhibitors"],"prefix":"10.1002","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7093-558X","authenticated-orcid":false,"given":"Blayne","family":"Welk","sequence":"first","affiliation":[{"name":"Department of Surgery Western University  London ON Canada"},{"name":"Institute for Clinical Evaluative Sciences  London, ON Canada"},{"name":"Department of Epidemiology and Biostatistics Western University  London ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"McArthur","sequence":"additional","affiliation":[{"name":"Institute for Clinical Evaluative Sciences  London, ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Ordon","sequence":"additional","affiliation":[{"name":"Division of Urology, Department of Surgery University of Toronto  Toronto ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jade","family":"Dirk","sequence":"additional","affiliation":[{"name":"Institute for Clinical Evaluative Sciences  London, ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Dixon","sequence":"additional","affiliation":[{"name":"Institute for Clinical Evaluative Sciences  London, ON Canada"},{"name":"Department of Epidemiology and Biostatistics Western University  London ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit X.","family":"Garg","sequence":"additional","affiliation":[{"name":"Institute for Clinical Evaluative Sciences  London, ON Canada"},{"name":"Department of Epidemiology and Biostatistics Western University  London ON Canada"},{"name":"Department of Medicine Western University  London ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,1,25]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2011.10195.x"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1515\/HMBCI.2010.035"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.4158\/EP12108.RA"},{"key":"e_1_2_11_5_1","unstructured":"Summary safety review\u2014finasteride\u2014assessing the potential risk of serious muscle\u2010related side effects\u2014Canada. ca.2017: 1\u20132. Available at:https:\/\/www.canada.ca\/en\/health\u2010canada\/services\/drugs\u2010health\u2010products\/medeffect\u2010canada\/safety\u2010reviews\/summary\u2010safety\u2010review\u2010finasteride\u2010assessing\u2010potential\u2010risk\u2010serious\u2010muscle\u2010related\u2010side\u2010effects.html. Accessed July 15 2017."},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-4598(199704)20:4<502::AID-MUS15>3.0.CO;2-#"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/ced.12570"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/CND.0b013e3181873cca"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2017.0089"},{"issue":"3","key":"e_1_2_11_10_1","first-page":"174","article-title":"Risk of adverse events among older adults following co\u2010prescription of clarithromycin and statins not metabolized by cytochrome P450 3A4","volume":"187","author":"Li DQ","year":"2014","journal-title":"Can Med Assoc J"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.292.21.2585"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0007182"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.4383","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.4383","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T01:40:37Z","timestamp":1695692437000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.4383"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,25]]},"references-count":11,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["10.1002\/pds.4383"],"URL":"https:\/\/doi.org\/10.1002\/pds.4383","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,25]]}}}